Progression of human immunodeficiency virus type 1 (HIV-1) infection among homosexual men in hepatitis b vaccine trial cohorts in Amsterdam, New York city, and San Francisco, 1978-1991

American Journal of Epidemiology

Volumn 139, Issue 11, 1994, Pages 1077-1087

  Hessol, Nancy A ^a   Koblin, Beryl A ^b   Van Griensven, Godfried J P ^c   Bacchetti, Peter ^d   Liu, Jennifer Y ^a   Stevens, Cladd E ^b   Coutinho, Roel A ^c   Buchbinder, Susan P ^a   Katz, Mitchell H ^a  

^a Department of Public Health ^*  (United States)

^b NEW YORK BLOOD CENTER   (United States)

^c MUNICIPAL HEALTH SERVICE   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acquired immunodeficiency syndrome; Age factors; HIV 1; Homosexuality; Kaposi's; Pneumocystis carinii; Pneumonia; Sarcoma; Survival; Zidovudine

Indexed keywords

HEPATITIS B VACCINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; HEPATITIS B; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION PREVENTION; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS CARINII; PNEUMOCYSTOSIS; SURVIVAL; UNITED STATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; COHORT STUDIES; HEPATITIS B; HEPATITIS B VACCINES; HIV SEROPOSITIVITY; HIV-1; HOMOSEXUALITY; HUMAN; MALE; NETHERLANDS; NEW YORK CITY; PROPORTIONAL HAZARDS MODELS; SAN FRANCISCO; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028303071     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a116951     Document Type: Article

References (41)

1. Taylor JMG, Schwartz K, Detels R. The time from infection with human immunodeficiency virus (HIV) to the onset of AIDS. J Infect Dis1986;154:694-7.
2. Moss AR, Bacchetti P, Osmond D, et al. Sero-positivity for HTV and the development of AIDS or AIDS-related condition: three-year follow-up of the San Francisco General Hospital cohort. Br Med J 1988;296:745-50.
3. Munoz A, Wang MC, Bass S, et al. Acquired immunodeficiency syndrome (AIDS)-free time after human immunodeficiency vims type 1 (HTV-1) seroconversion in homosexual men. Multicenter AIDS Cohort Study Group. Am J Epidemiol 1989;130:530-9.
4. Rutherford GW, Lifson AR, Hessol NA, et al.Course of HIV-1 infection in a cohort of homosexual and bisexual men: an 11-year follow-up study. BMJ 1990;301:1183-8.
5. van Griensven GJP, de Vroome EMM, de Wolf F, et al. Risk factors for progression of human immunodeficiency virus (HIV) infection among seroconverted and seropositive homosexual men. Am J Epidemiol 1990;132:203-10.
6. Szmuness W, Stevens C, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980;303: 833-41.
7. Coutinho RA, Schut BJT, Albrecht-van Lent N, et al. Hepatitis B among homosexual men in the Netherlands. Sex Transm Dis 1981;8:333-5.
8. Schreeder MT, Thompson SE, Hadler SC, et al.Hepatitis B in homosexual men: prevalence of infection and factors related to transmission. J Infect Dis 1982;146:7-15.
9. Francis DP, Hadler SC, Sumner E, et al. The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med 1982;97:362-6.
10. Coutinho RA, Lelie N, Albrecht-van Lent N, et al. Efficacy of a heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo-controlled trial. Br Med J 1983;286:1305-8.
11. van Griensven GJP, Tielman RAP, Goudsmit J, et al. Risk factors and prevalence of HTV antibodies among homosexual men in the Netherlands. Am J Epidemiol 1987;125:1048-57.
12. van Griensven GJP, de Vroome EMM, Goudsmit J, et al. Changes in sexual behavior and the fall in incidence of HIV infection among homosexual men. BMJ 1989;298:218-21.
13. Stevens CE, Taylor PE, Zang EA, et al. Human T cell lymphotrophic virus type III infection in a cohort of homosexual men in New York City. JAMA 1986;255:2167-72.
14. Jaffe HW, Darrow WW, Echenberg DF, et al.The acquired immunodeficiency syndrome in a cohort of homosexual men: a six-year follow-up study. Ann Intern Med 1985;97:362-6.
15. Hessol NA, Lifson AR, O’Malley PM, et al.Prevalence, incidence, and progression of human immunodeficiency virus infection in homosexual and bisexual men in hepatitis B vaccine trials, 1978-1988. Am J Epidemiol 1989;130:1167-75.
16. Koblin BA, van Griensven GJP, Hessol NA, et al. HIV-1 infection rates in three hepatitis B vaccine cohorts-Amsterdam, New York, and San Francisco, 1978-1990. Presented at the 7th International Conference on AIDS, Florence, Italy, June 1991.
17. van Griensven GJP, Hessol NA, Koblin BA, et al. Epidemiology of human immunodeficiency virus type 1 infection among homosexual men participating in hepatitis B vaccine trials in Amsterdam, New York City, and San Francisco, 1978-1990. Am J Epidemiol 1993;137:909-15.
18. Bacchetti P. Estimating the incubation period of AIDS by comparing population infection and diagnosis patterns. J Am Stat Assoc 1990;85: 1002-8.
19. Dixon WJ, ed. BMDP statistical software. Los Angeles, CA: University of California Press, 1985.
20. Harrell FE, Lee KL Verifying assumptions of the Cox proportional hazards model. In: Proceedings of the 11th Annual SAS User’s Group International Conference. Cary, NC: SAS Institute, 1986.
21. Hoover DR, Munoz A, He Y, et al. The effectiveness of interventions on incubation of AIDS as measured by secular increases within a population. Stat Med (in press).
22. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36(Suppl 1):3S-15S.
23. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-rplated complex: a double-blind placebo-controlled trial. N Engl J Med 1987;317:185-91.
24. Volberding PA, Lagakos SW, Koch MA, et al.Zidovudine in asymptomatic human immunodeficiency virus infection: as controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;322: 941-9.
25. Girard PM, Landman R, Gaudebout C, et al.Prevention of Pneumocystis carinii pneumonia relapse by pentamidine aerosol in zidovudine-treated AIDS patients. Lancet 1989;1:1348-53.
26. Leoung GS, Feigal DW, Montgomery AB, et al.Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. N Engl J Med1990;323:769-75.
27. Hirschel B, Lazzarin A, Chopard P, et al. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med 1991;324:1079-83.
28. Rothenberg R, Woelfel M, Stonebumer R, et al.Survival with the acquired immunodeficiency syndrome: experience with 5833 cases in New York City. N Engl J Med 1987;317:1297-302.
29. Bacchetti P, Osmond D, Chaisson RE, et al. Survival patterns of the first 500 patients with AIDS in San Francisco. J Infect Dis 1988;157:1004-7.
30. Lemp GF, Payne SF, Neal D, et al. Survival trends for patients with AIDS. JAMA 1990;263: 402-6.
31. Goedert JJ, Kessler CM, Aledort LM, et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med1989;321:1141-8.
32. Phillips AN, Lee CA, Elford J, et al. More rapid progression to AIDS in older HIV-infected people: the role of CD44 T-cell counts. J Acquir Immune Defic Syndr 1991;4:970-5.
33. Tersmette M, Graters RA, de Wolf F, et al. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol 1989;63: 2118-25.
34. 4+ cell count decline during progression to AIDS correlates with HTV-1 phenotype. AIDS 1992;6:665-9.
35. Hoover DR, Munoz A, Carey V, et al. Using events from dropouts in nonparametric survival function estimation with application to incubation of AIDS. J Am Stat Assoc 1993;88:37-13.
36. Kaposi’s sarcoma and Pneumocystis pneumonia among homosexual men-New York City and California. MMWR 1981;30:305-8.
37. Lang W, Osmond D, Samuel M, et al. Population-based estimates of zidovudine and aerosol pentamidine use in San Francisco: 1987-1989. J Acquir Immune Defic Syndr 1991;4:713-716.
38. Rosenberg PS, Gail MH, Schrager LK, et al.National AIDS incidence trends and the extent of zidovudine therapy in selected demographic and transmission groups. J Acquir Immune Defic Syndr 1991;4:392-401.
39. Graham NMH, Zeger SL, Kuo V, et al. Zidovudine use in AIDS-free HIV-l-seropositive homosexual men in the Multicenter AIDS Cohort Study (MACS), 1987-1989. J Acquir Immune Defic Syndr 1991;4:267-76.
40. Brookmeyer R. Reconstruction and future trends of the AIDS epidemic in the United States. Science 1991;253:37-42.
41. Gail MH, Rosenberg PS. Perspectives on using back calculation to estimate HIV prevalence and project AIDS incidence. In: Jewel NP, Dietz K, Farewell VT, eds: AIDS epidemiology: methodological issues. Boston, MA: Birkhauser-Boston Publishers, 1992:1-38.